AI
EWTX icon

Atom Investors’s Edgewise Therapeutics EWTX Stock Holding History

Atom Investors’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-9,941
Closed -$313K – 895
2026
Q1 		$313K Buy
+9,941
New +$287K 0.02% 542
2022
Q2 		– Sell
-15,781
Closed -$153K – 273
2022
Q1 		$153K Buy
+15,781
New +$203K 0.07% 172

Other funds holding EWTX

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Atom Investors's EWTX Position: Q2 2026 in Review

Atom Investors sold out of Edgewise Therapeutics (EWTX) in Q2 2026, closing a stake of 9,941 shares — an estimated $313K sold.

Atom Investors first reported a position in EWTX in Q1 2022 and held it in 2 quarters. The position peaked at $313K in Q1 2026. 226 funds tracked by Wall St. Rank hold EWTX as of Q2 2026.

  • Atom Investors reported no remaining Edgewise Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Atom Investors sold 9,941 Edgewise Therapeutics shares in Q2 2026, an estimated $313K.
  • Atom Investors first reported a position in Edgewise Therapeutics in Q1 2022 and held it in 2 quarters.
  • Atom Investors's Edgewise Therapeutics position peaked at $313K in Q1 2026.
  • 226 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q2 2026.

Based on Atom Investors's 13F filing for Q2 2026, filed 14 Aug 2026.